Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 11/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407653 | 0.88 | DGAT1 (0.49) | DGAT1KDM4EALDH1A1MAPK1NPSR1 | |
| SCHEMBL407225 | 0.87 | DGAT1 (0.48) | DGAT1KDM4EALDH1A1MAPK1NPSR1 | |
| SCHEMBL442691 | 0.87 | DGAT1 (0.61) | DGAT1KDM4EALDH1A1MAPK1NPSR1 | |
| SCHEMBL407661 | 0.85 | DGAT1 (0.47) | DGAT1KDM4EALDH1A1MAPK1NPSR1 | |
| SCHEMBL408667 | 0.84 | DGAT1 (0.43) | DGAT1KDM4EALDH1A1MAPK1NPSR1 | |
| SCHEMBL408172 | 0.83 | NPSR1 (0.60) | DGAT1ALDH1A1MAPK1NPSR1 | |
| SCHEMBL22493023 | 0.82 | MAPT (0.45) | DGAT1ALDH1A1MAPK1NPSR1 | |
| SCHEMBL408728 | 0.81 | DGAT1 (0.47) | DGAT1ALDH1A1 | |
| SCHEMBL408365 | 0.81 | DGAT1 (0.59) | DGAT1KDM4EALDH1A1MAPK1NPSR1 | |
| SCHEMBL20304409 | 0.79 | TDP1 (0.46) | DGAT1KDM4EMAPK1NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | PDE4B 1423/4885DGAT1 2/4885KDM4E 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.